Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis

Funda Tamer; Fatma Gülru Erdoğan; Dilsun Yıldırım; Didem Rota

Case Report

Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis

Year 2018, Volume: 71 Issue: 2, 177 - 180, 10.10.2018

Funda Tamer , Fatma Gülru Erdoğan , Dilsun Yıldırım Didem Rota

Abstract

Omalizumab selectively binds to immunoglobulin E antibodies and is approved for treatment of allergic asthma. However, its use in dermatologic diseases is increasing. Here, we report three treatment resistant cases, one with atopic dermatitis the other two with contact dermatitis successfully treated with omalizumab with no side effect.

Keywords

Atopic Dermatitis , Contact Dermatitis , Omalizumab

References

1. El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol 2016;50:84-96.
2. Chia JC, Mydlarski PR. Dermatologic uses of omalizumab. J Dermatolog Treat 2017;28:332-337.
3. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy 2015;45:566-574.
4. Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol 2012;129:879-886.
5. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014;133:1615-1625.
6. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013;38:496-500.
7. Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22:349-352.
8. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol 2016;138:1719-1722.
9. Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 2016;96:72-76.
10. Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: Patient management and education. J Am Acad Dermatol 2016;74:1043- 1054.
11. Kostner L, Anzengruber F, Guillod C, et al. Allergic contact dermatitis. Immunol Allergy Clin North Am 2017;37:141-152.
12. Mur Gimeno P, Martín Iglesias A, Lombardero Vega M, et al. Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol 2013;23:287-288.
13. Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104:188- 196.
14. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-465.
15. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-1154

Omalizumabin Tedaviye Dirençli Atopik Dermatit ve Kontakt Dermatit Tedavisindeki Etkinliği

Year 2018, Volume: 71 Issue: 2, 177 - 180, 10.10.2018

Funda Tamer , Fatma Gülru Erdoğan , Dilsun Yıldırım Didem Rota

Abstract

Omalizumab selektif olarak immünoglobulin E antikorlarına bağlanır ve alerjik astım tedavisi için onaylanmıştır. Bununla birlikte dermatolojik hastalıklarda kullanımı giderek artmaktadır. Bu makalede, omalizumab ile başarılı bir şekilde ve yan etki görülmeden tedavi edilmiş biri atopik dermatitli, diğer ikisi kontakt dermatitli olmak üzere tedaviye direnç gösteren üç olgu sunduk.

Keywords

Atopik Dermatit , Kontakt Dermatit , Omalizumab

References

1. El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol 2016;50:84-96.
2. Chia JC, Mydlarski PR. Dermatologic uses of omalizumab. J Dermatolog Treat 2017;28:332-337.
3. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy 2015;45:566-574.
4. Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol 2012;129:879-886.
5. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014;133:1615-1625.
6. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013;38:496-500.
7. Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22:349-352.
8. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol 2016;138:1719-1722.
9. Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 2016;96:72-76.
10. Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: Patient management and education. J Am Acad Dermatol 2016;74:1043- 1054.
11. Kostner L, Anzengruber F, Guillod C, et al. Allergic contact dermatitis. Immunol Allergy Clin North Am 2017;37:141-152.
12. Mur Gimeno P, Martín Iglesias A, Lombardero Vega M, et al. Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol 2013;23:287-288.
13. Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104:188- 196.
14. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-465.
15. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-1154

There are 15 citations in total.

Details

Primary Language	English
Subjects	Dermatology
Journal Section	Case Report
Authors	Funda Tamer 0000-0003-4157-5583 Fatma Gülru Erdoğan 0000-0002-7102-7329 Dilsun Yıldırım This is me 0000-0002-9144-6790 Didem Rota 0000-0002-3772-6943
Publication Date	October 10, 2018
Published in Issue	Year 2018 Volume: 71 Issue: 2

Cite

APA	Tamer, F., Erdoğan, F. G., Yıldırım, D., Rota, D. (2018). Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 71(2), 177-180.
AMA	Tamer F, Erdoğan FG, Yıldırım D, Rota D. Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis. Ankara Üniversitesi Tıp Fakültesi Mecmuası. October 2018;71(2):177-180.
Chicago	Tamer, Funda, Fatma Gülru Erdoğan, Dilsun Yıldırım, and Didem Rota. “Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 71, no. 2 (October 2018): 177-80.
EndNote	Tamer F, Erdoğan FG, Yıldırım D, Rota D (October 1, 2018) Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis. Ankara Üniversitesi Tıp Fakültesi Mecmuası 71 2 177–180.
IEEE	F. Tamer, F. G. Erdoğan, D. Yıldırım, and D. Rota, “Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis”, Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 71, no. 2, pp. 177–180, 2018.
ISNAD	Tamer, Funda et al. “Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 71/2 (October2018), 177-180.
JAMA	Tamer F, Erdoğan FG, Yıldırım D, Rota D. Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2018;71:177–180.
MLA	Tamer, Funda et al. “Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis”. Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 71, no. 2, 2018, pp. 177-80.
Vancouver	Tamer F, Erdoğan FG, Yıldırım D, Rota D. Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2018;71(2):177-80.